Robak, Tadeusz <br/><br/>
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study  [electronic resource] 

 -  Leukemia & lymphoma  01 2019 
 - 172-179 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2017.1321750  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bortezomib--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Progression-Free Survival<br/>Survival Analysis